This release is intended for distribution in Canada only and is not to be distributed to United States newswire services or disseminated in the United States.

TORONTO , Ontario – January 11, 2006 : NeuroMedix Inc. (“NeuroMedix”) announces that it has filed a final prospectus with the securities regulatory authorities in Ontario , Alberta and British Columbia in connection with its initial public offering of common shares (the “Offering”). The Offering consists of a minimum of 11,000,000 and a maximum of 12,000,000 common shares at a price of $0.25 per share, for gross proceeds of up to $3,000,000. The placement agent for the Offering, Dundee Securities Corporation, has also been granted an over-allotment option to purchase, on the same terms and conditions as the Offering, up to an additional 10% of the Offering. The over-allotment option is exercisable for a period of 30 days from the date of the closing of the Offering.

The financing is expected to close on or about January 24, 2006 . NeuroMedix expects to receive between $2.2 million and $2.5 million in net proceeds from the Offering ($2.7 million if the over-allotment option is exercised in full) and intends to use these funds for research and development and general and administrative expenses, including working capital.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease, multiple sclerosis and Parkinson's disease. Our therapeutic candidates are based on research from a team of leading experts in the field of neuroinflammation and have been demonstrated, in pre-clinical studies, to reduce brain inflammation, protect neuronal cells, restore cognitive function and ultimately prevent the development of Alzheimer's disease.

For further information on NeuroMedix, visit www.neuromedixinc.com or contact:

Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
mark@neuromedixinc.com

Catherine Auld, CA
Chief Financial Officer
NeuroMedix Inc.
cathy@neuromedixinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.